Partnership to Accelerate Development of Ovarian Cancer Test
A strategic partnership has formed to accelerate the development a test for early ovarian cancer diagnosis using AI-powered analytics.
A strategic partnership has formed to accelerate the development a test for early ovarian cancer diagnosis using AI-powered analytics.
AI-based models can surpass human experts in diagnosing ovarian cancer from ultrasound images, promising more accurate patient care.
An AI-powered blood test combining DNA fragment analysis with protein biomarkers significantly improves early ovarian cancer detection.
A blood test measuring lymphocyte levels may predict the effectiveness of CAR-T immunotherapy in relapsed multiple myeloma patients.
Read MoreA new machine-learning serum fusion-gene model shows promise in increasing hepatocellular carcinoma diagnostic accuracy and monitoring.
Read MoreResearcher identified a 15-gene signature biomarker that can stratify renal cancer patients into low or high risk of recurrence.
Read MoreA new genotyping test using cerebrospinal fluid can rapidly diagnose brain cancers, reducing the need for invasive biopsies.
Read MoreResearchers discovered a novel immune-based biomarker that could pave the way for potential early detection of high-grade ovarian cancer.
Read MoreA clinical trial shows that a Helio Genomics test outperforms ultrasound in detecting hepatocellular carcinoma in liver cirrhosis patients.
Read MoreSalignostics has partnered with ARC Innovation at Sheba Medical Center to develop a saliva-based test for detecting oral cavity cancer.
Read MoreMercy BioAnalytics will present data showing that their Mercy Halo test significantly improves early detection of ovarian cancer.
Read MoreResearchers discovered new biomarkers for renal cell carcinomas, enhancing the diagnosis of various subtypes.
Read MoreThe tumor cell enumeration assay is a diagnostic test that is promising for establishing the diagnosis of leptomeningeal metastases.
Read MoreThe U.S. Patent and Trademark Office issued a patent to Myriad Genetics aimed at strengthening its ability to deliver a MRD assay to market.Â
Read MoreA new algorithm may help identify high-risk precancerous lesions on the fallopian tubes thought to lead to a common form of ovarian cancer
Read MoreThe Oncuria Bladder Cancer Tests, a DiaCarta validated lab developed test (LDT), received Medicare coverage effective Jan. 1, 2024.
Read MoreResearchers have developed a new biosensor using terahertz waves that can detect skin cancer with improved sensitivity.
Read MoreLucid Diagnostics has contracted with the World Trade Center Health Program to provide the EsoGuard Esophageal DNA test as a covered benefit.
Read More